BACKGROUND: Limited 5-year data exist on clinical outcomes and toxicities for patients undergoing 3-dimensional conformal radiation therapy (3D-CRT) APBI. PATIENTS AND METHODS: Two hundred five patients were treated with 3D-CRT APBI between August, 2000 and December, 2011. Cases with > 1 year of follow-up were analyzed for cosmesis, chronic toxicities, and clinical outcomes. Outcome by American Society for Radiation Oncology (ASTRO) Consensus Panel (CP) group were also compared. Rates of excellent and good cosmesis for 3D-CRT were evaluated over time for stability. RESULTS: One hundred ninety-two patients were evaluated; median follow-up was 4.8 years (range, 1.0-11.2 years). Seventy-two patients (37.5%) were categorized as ASTRO CP subgroup 'suitable,' 89 (46.4%) 'cautionary,' and 31 (16.1%) 'unsuitable.' At 5 years, the rate of IBTR, regional recurrence, distant metastases, cause-specific survival, and overall survival were 0%, 0%, 2%, 99%, and 92%, respectively. Thirty-seven percent of patients had excellent cosmesis, 44% good cosmesis, 15% fair cosmesis, and 4% poor cosmesis. No statistically significant differences in excellent (37% vs. 37%; P = .99) or good (49% vs. 37%; P = .28) cosmesis were noted between patients with < 5 years follow-up and those with ≥ 5 years follow-up. The rates of grade III fibrosis and telangiectasia were 7.5% and 7.6%, respectively. CONCLUSION: In the largest group of patients published to date using 3D-CRT to deliver APBI, no local recurrences were noted at 5 years. More than 80% of patients had excellent or good cosmesis.
BACKGROUND: Limited 5-year data exist on clinical outcomes and toxicities for patients undergoing 3-dimensional conformal radiation therapy (3D-CRT) APBI. PATIENTS AND METHODS: Two hundred five patients were treated with 3D-CRT APBI between August, 2000 and December, 2011. Cases with > 1 year of follow-up were analyzed for cosmesis, chronic toxicities, and clinical outcomes. Outcome by American Society for Radiation Oncology (ASTRO) Consensus Panel (CP) group were also compared. Rates of excellent and good cosmesis for 3D-CRT were evaluated over time for stability. RESULTS: One hundred ninety-two patients were evaluated; median follow-up was 4.8 years (range, 1.0-11.2 years). Seventy-two patients (37.5%) were categorized as ASTRO CP subgroup 'suitable,' 89 (46.4%) 'cautionary,' and 31 (16.1%) 'unsuitable.' At 5 years, the rate of IBTR, regional recurrence, distant metastases, cause-specific survival, and overall survival were 0%, 0%, 2%, 99%, and 92%, respectively. Thirty-seven percent of patients had excellent cosmesis, 44% good cosmesis, 15% fair cosmesis, and 4% poor cosmesis. No statistically significant differences in excellent (37% vs. 37%; P = .99) or good (49% vs. 37%; P = .28) cosmesis were noted between patients with < 5 years follow-up and those with ≥ 5 years follow-up. The rates of grade III fibrosis and telangiectasia were 7.5% and 7.6%, respectively. CONCLUSION: In the largest group of patients published to date using 3D-CRT to deliver APBI, no local recurrences were noted at 5 years. More than 80% of patients had excellent or good cosmesis.
Authors: Janet K Horton; Rachel C Blitzblau; Sua Yoo; Joseph Geradts; Zheng Chang; Jay A Baker; Gregory S Georgiade; Wei Chen; Sharareh Siamakpour-Reihani; Chunhao Wang; Gloria Broadwater; Jeff Groth; Manisha Palta; Mark Dewhirst; William T Barry; Eileen A Duffy; Jen-Tsan A Chi; E Shelley Hwang Journal: Int J Radiat Oncol Biol Phys Date: 2015-03-14 Impact factor: 7.038
Authors: Rachel Y Lei; Charles E Leonard; Kathryn T Howell; Phyllis L Henkenberns; Timothy K Johnson; Tracy L Hobart; Shannon P Fryman; Jane M Kercher; Jodi L Widner; Terese Kaske; Dennis L Carter Journal: Breast Cancer Res Treat Date: 2013-07-04 Impact factor: 4.872
Authors: Sharad Goyal; Parima Daroui; Atif J Khan; Thomas Kearney; Laurie Kirstein; Bruce G Haffty Journal: Cancer Med Date: 2013-10-31 Impact factor: 4.452
Authors: Amira Ziouèche-Mottet; Gilles Houvenaeghel; Jean Marc Classe; Jean Rémi Garbay; Sylvia Giard; Hélène Charitansky; Monique Cohen; Catherine Belichard; Christelle Faure; Elisabeth Chéreau Ewald; Delphine Hudry; Pierre Azuar; Richard Villet; Pierre Gimbergues; Christine Tunon de Lara; Agnès Tallet; Marie Bannier; Mathieu Minsat; Eric Lambaudie; Michel Resbeut Journal: BMC Cancer Date: 2014-11-24 Impact factor: 4.430
Authors: Eric Lambaudie; Gilles Houvenaeghel; Amira Ziouèche; Sophie Knight; François Dravet; Jean Remy Garbay; Sylvie Giard; Hélène Charitansky; Monique Cohen; Christelle Faure; Delphine Hudry; Paul Azuar; Richard Villet; Pierre Gimbergues; Christine Tunon de Lara; Agnès Tallet; Marie Bannier; Mathieu Minsat; Michel Resbeut Journal: BMC Surg Date: 2016-11-15 Impact factor: 2.102